CN1832929B - 用于治疗瘤形成疾病、炎症和免疫系统疾病的2,4-嘧啶二胺 - Google Patents
用于治疗瘤形成疾病、炎症和免疫系统疾病的2,4-嘧啶二胺 Download PDFInfo
- Publication number
- CN1832929B CN1832929B CN2004800227255A CN200480022725A CN1832929B CN 1832929 B CN1832929 B CN 1832929B CN 2004800227255 A CN2004800227255 A CN 2004800227255A CN 200480022725 A CN200480022725 A CN 200480022725A CN 1832929 B CN1832929 B CN 1832929B
- Authority
- CN
- China
- Prior art keywords
- amino
- methyl
- base
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZWMDEVPYVGQJHU-UHFFFAOYSA-N CN(C)S(c(cccc1)c1Nc(nc(Nc(c(OC)c1)ccc1N1CCOCC1)[n]c1)c1Br)(=O)=O Chemical compound CN(C)S(c(cccc1)c1Nc(nc(Nc(c(OC)c1)ccc1N1CCOCC1)[n]c1)c1Br)(=O)=O ZWMDEVPYVGQJHU-UHFFFAOYSA-N 0.000 description 1
- NRPNUOKRHRYIBP-UHFFFAOYSA-N CNC(c1ccccc1Nc(nc(nc1)Cl)c1Cl)=O Chemical compound CNC(c1ccccc1Nc(nc(nc1)Cl)c1Cl)=O NRPNUOKRHRYIBP-UHFFFAOYSA-N 0.000 description 1
- HJVNHZGCYWWRMV-UHFFFAOYSA-N Cc(cc1)cc(OC)c1Nc(nc1)nc(Nc(cccc2)c2S(NCC(F)(F)F)(=O)=O)c1Cl Chemical compound Cc(cc1)cc(OC)c1Nc(nc1)nc(Nc(cccc2)c2S(NCC(F)(F)F)(=O)=O)c1Cl HJVNHZGCYWWRMV-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N Clc(c(Cl)n1)cnc1Cl Chemical compound Clc(c(Cl)n1)cnc1Cl GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0319227.5 | 2003-08-15 | ||
| GB0319227A GB0319227D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
| GB0322370.8 | 2003-09-24 | ||
| GB0322370A GB0322370D0 (en) | 2003-09-24 | 2003-09-24 | Organic compounds |
| PCT/EP2004/009099 WO2005016894A1 (en) | 2003-08-15 | 2004-08-13 | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1832929A CN1832929A (zh) | 2006-09-13 |
| CN1832929B true CN1832929B (zh) | 2012-11-07 |
Family
ID=28052593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800227255A Expired - Lifetime CN1832929B (zh) | 2003-08-15 | 2004-08-13 | 用于治疗瘤形成疾病、炎症和免疫系统疾病的2,4-嘧啶二胺 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1832929B (es) |
| AR (2) | AR107965A2 (es) |
| GB (1) | GB0319227D0 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101149295B1 (ko) * | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| CA2762108A1 (en) * | 2009-05-15 | 2010-11-18 | Insight Genetics, Inc. | Methods and compositions relating to fusions of alk for diagnosing and treating cancer |
| KR102156398B1 (ko) * | 2012-11-06 | 2020-09-15 | 상하이 포천 파마슈티컬 씨오 엘티디 | Ａｌｋ 키나아제 억제제 |
| US10202356B2 (en) * | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
| CN104926794B (zh) * | 2014-03-17 | 2017-12-05 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| CN106008503B (zh) * | 2015-03-31 | 2020-09-01 | 齐鲁制药有限公司 | 螺环芳基砜作为蛋白激酶抑制剂 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
| CN106349224A (zh) * | 2016-08-03 | 2017-01-25 | 山东大学 | 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用 |
| CN110092759A (zh) * | 2018-01-31 | 2019-08-06 | 陆柯潮 | 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物 |
| CN114716385B (zh) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | 靶向粘着斑激酶的化合物及制备方法和应用 |
| CN118878468A (zh) * | 2024-07-11 | 2024-11-01 | 贵州大学 | 一种含苯基氮芥片段的二氨基嘧啶类化合物及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078404A1 (en) * | 2002-03-15 | 2003-09-25 | Novartis Ag | Pyrimidine derivatives |
-
2003
- 2003-08-15 GB GB0319227A patent/GB0319227D0/en not_active Ceased
-
2004
- 2004-08-13 CN CN2004800227255A patent/CN1832929B/zh not_active Expired - Lifetime
-
2017
- 2017-03-23 AR ARP170100728A patent/AR107965A2/es unknown
-
2019
- 2019-02-04 AR ARP190100267A patent/AR114354A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078404A1 (en) * | 2002-03-15 | 2003-09-25 | Novartis Ag | Pyrimidine derivatives |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1832929A (zh) | 2006-09-13 |
| AR107965A2 (es) | 2018-07-04 |
| AR114354A2 (es) | 2020-08-26 |
| GB0319227D0 (en) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1788001B (zh) | 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4-二(苯氨基)嘧啶 | |
| EP2287156B1 (en) | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | |
| TWI752580B (zh) | Kras突變蛋白抑制劑 | |
| CN103121972B (zh) | 作为激酶抑制剂的嘧啶脲衍生物 | |
| CN1832929B (zh) | 用于治疗瘤形成疾病、炎症和免疫系统疾病的2,4-嘧啶二胺 | |
| CA2917735C (en) | Protein tyrosine kinase modulators and methods of use | |
| US8519129B2 (en) | Pyrimidine derivatives as kinase inhibitors | |
| EP2323987B1 (en) | N-myristoyl transferase inhibitors | |
| US10342796B2 (en) | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | |
| ES2308821T3 (es) | Nuevos derivados de pirimidin-5-carboxamida. | |
| TW200406374A (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| TW200521118A (en) | Pyrimidine derivatives | |
| JP2004502763A5 (es) | ||
| NZ523357A (en) | Pyrimidine derivatives | |
| JP2008510763A (ja) | ピリミジン誘導体 | |
| HU228449B1 (en) | Antiviral compositions | |
| WO2008132138A1 (en) | Derivatives of 4,6-disubstituted aminopyrimidines | |
| CN101137382A (zh) | 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂 | |
| WO2018203691A1 (ko) | 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 tyro 3관련 질환의 예방 또는 치료용 조성물 | |
| TW201915004A (zh) | 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用 | |
| US20160074399A1 (en) | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor | |
| CN101323629A (zh) | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-甲基磷酸二乙酯 | |
| CN101291917A (zh) | 治疗蛋白激酶依赖性疾病的二芳基脲衍生物 | |
| KR20190027765A (ko) | 피라졸기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 | |
| KR20190027766A (ko) | 테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CI02 | Correction of invention patent application |
Correction item: Priority Correct: 2003.09.24 GB 0322370.8 False: Lack of priority second Number: 37 Page: The title page Volume: 22 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: PRIORITY; FROM: MISSING THE SECOND ARTICLE OF PRIORITY TO: 2003.9.24 GB 0322370.8 |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Basel, Switzerland Patentee after: NOVARTIS AG Patentee after: IRM LLC Address before: Basel, Switzerland Patentee before: Novartis AG Patentee before: IRM LLC |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160121 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Basel, Switzerland Patentee before: Novartis Ag Patentee before: Novartis international pharmaceuticals Ltd. Effective date of registration: 20160121 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Patentee after: Novartis international pharmaceuticals Ltd. Address before: Basel, Switzerland Patentee before: Novartis Ag Patentee before: IRM LLC |
|
| CX01 | Expiry of patent term |
Granted publication date: 20121107 |
|
| CX01 | Expiry of patent term |